| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | 1 | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2026 | 2.25 |
—
—
—
|
| 2025 | 2.96 |
—
—
—
—
|
| 2024 | 2.92 |
—
—
—
—
|
| 2023 | 2.88 |
—
—
—
—
|
| 2022 | 2.84 |
—
—
—
—
|
| 2021 | 2.80 |
—
—
—
—
|
| 2020 | 2.76 |
—
—
—
—
|
| 2019 | 2.72 |
—
—
—
—
|
| 2018 | 2.68 |
—
—
—
—
|
| 2017 | 2.64 |
—
—
—
—
|
| 2016 | 2.60 |
—
—
—
—
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 8.21 | 7.10 | 6.69 | 6.82 |
| Receivables | 83.28 | 82.80 | 82.15 | 81.74 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 91.49 | 89.90 | 88.83 | 88.56 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | — | — | — | — |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 13.99 | 11.14 | 14.70 | 15.97 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 24.53 | 24.99 | — | — |
—
|
| ’25 | 24.55 | 24.87 | 25.30 | 24.47 |
99.19
|
| ’24 | 25.14 | 24.73 | 24.49 | 24.64 |
99.01
|
| ’23 | 23.23 | 23.81 | 24.22 | 24.32 |
95.58
|
| ’22 | 22.18 | 22.17 | 22.15 | 24.13 |
90.63
|
| ’21 | 20.70 | 20.88 | 21.21 | 21.41 |
84.19
|
| ’20 | 19.21 | 19.28 | 19.69 | 19.83 |
78.01
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 11.95 | 12.41 | — | — |
—
|
| ’25 | 11.61 | 13.69 | 10.20 | 13.60 |
49.09
|
| ’24 | 11.74 | 12.13 | 9.89 | 13.15 |
46.91
|
| ’23 | 10.07 | 12.25 | 10.16 | 10.46 |
42.94
|
| ’22 | 11.70 | 13.24 | 9.58 | 12.29 |
46.81
|
| ’21 | 11.25 | 14.15 | 10.80 | 11.53 |
47.73
|
| ’20 | 10.14 | 13.07 | 9.57 | 11.44 |
44.21
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 7.68 | 3.55 | — | — |
—
|
| ’25 | 10.04 | 11.54 | 8.61 | 10.06 |
40.26
|
| ’24 | 8.44 | 11.09 | 8.96 | 9.35 |
37.84
|
| ’23 | 8.53 | 4.90 | (0.77) | 14.69 |
27.36
|
| ’22 | (5.27) | 5.37 | 4.10 | 20.12 |
24.32
|
| ’21 | 4.08 | (0.09) | 7.48 | 8.95 |
20.42
|
| ’20 | 4.62 | 10.48 | 4.09 | 1.02 |
20.21
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.36 | 0.43 | — | — |
—
|
| ’25 | 0.34 | 0.32 | 0.29 | 0.31 |
1.27
|
| ’24 | 0.38 | 0.38 | 0.29 | 0.34 |
1.39
|
| ’23 | 0.32 | 0.25 | 0.28 | 0.26 |
1.11
|
| ’22 | 0.39 | 0.38 | 0.35 | 0.41 |
1.53
|
| ’21 | 0.41 | 0.48 | 0.39 | 6.65 |
7.92
|
| ’20 | 0.33 | 0.34 | 0.38 | 0.36 |
1.41
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 40.92 | 37.00 | 32.27 | 34.56 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 61.32 | 57.52 | 47.30 | 43.00 | — | — | — |
High Price
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 90.63 | 95.58 | 99.01 | 99.19 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 94.38% | 94.43% | 94.46% | 94.36% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.91 | 14.19 | 17.96 | 15.91 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21.97% | 14.85% | 18.13% | 16.04% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21.10 | 15.40 | 19.23 | 17.61 | — | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 27.08 | 28.28 | 28.01 | 29.45 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.58 | 6.93 | 7.17 | 7.18 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 1.53 | 1.12 | 1.39 | 1.27 | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.40 | 3.11 | 3.40 | 3.55 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.63) | (1.13) | (0.66) | (0.64) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.77 | 1.98 | 2.74 | 2.91 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 16.64 | 14.58 | 13.01 | 11.03 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13.77 | 13.79 | 13.80 | 13.82 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 31.42 | 39.56 | 26.77 | 30.63 | — | — | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.30 | 6.33 | 5.19 | 5.46 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.89 | 3.01 | 2.86 | 3.56 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.12 | 10.08 | 8.90 | 9.24 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 41.43 | 35.21 | 23.29 | 22.76 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 46.81 | 42.94 | 46.91 | 49.09 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (22.48) | (15.58) | (9.07) | (8.84) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 24.32 | 27.36 | 37.84 | 40.26 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 91.80 | 77.50 | 78.76 | 74.14 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 353.27 | 359.46 | 368.25 | 374.64 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 345.66 | 351.25 | 361.15 | 367.95 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 229.10 | 200.93 | 179.54 | 152.38 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.50% | 2.56% | 3.27% | 3.07% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.33% | 3.55% | 4.25% | 4.18% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.09% | 7.16% | 10.11% | 10.61% | — | — | — |
ROE
|
Universal Health Realty Income Trust (UHT), a healthcare-focused REIT, boasts reliable revenue growth at a 5% CAGR from $67.1 million in 2016 to $99.0 million in 2024, underpinned by stable 94-95% gross margins and resilient medical office/hospital leases that weathered COVID disruptions. Free cash flow per share strengthened to $2.74 in 2024 (up 38% YoY), supporting dividends, while analysts project modest 2-3% annual revenue gains through 2027. However, profitability volatility—net income swinging from $109.2 million in 2021 to $19.2 million in 2024—combined with a recent CEO insider buy of $453K shares, hints at underlying operational steadiness amid sector tailwinds like aging demographics.
The balance sheet tells a cautionary tale: total debt ballooned to $368.2 million (up 32% since 2017), shareholders’ equity shrank 24% to $179.5 million over three years, and stock prices plunged 45-70% from pandemic highs despite per-share revenue gains. Valuations have compressed (PS at 5.2x, PE at 26.8x), trading near consensus targets in a rate-sensitive sector prone to policy risks like Medicare changes, positioning UHT as a steady but unexciting yield play for conservative investors—potentially a value trap if leverage persists.
This analysis unpacks downside protection via cash flow sustainability against leverage risks and a decade of shareholder value erosion, revealing why UHT merits a cautious hold. Dive into the full breakdown for quantitative models, peer benchmarks, and key monitors like Q1 2026 debt metrics.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.